From professional translators, enterprises, web pages and freely available translation repositories.
vlasatobunkovou
hairy cell
Last Update: 2020-12-19
Usage Frequency: 1
Quality:
Reference:
liečba pacientov s vlasatobunkovou leukémiou.
treatment of patients with hairy cell leukaemia.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
predpokladá sa, že u pacientov s vlasatobunkovou leukémiou vzniknú sekundárne malígne afekcie.
secondary malignancies are expected to occur in patients with hairy cell leukaemia.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
Štyridsaťtri percent pacientov s vlasatobunkovou leukémiou malo infekčné komplikácie pri štandardnom režime dávkovania.
forty-three percent of patients with hairy cell leukaemia experienced infectious complications at standard dose regimen.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
litak sa skúmal v jednej hlavnej štúdii, ktorá zahŕňala 63 pacientov s vlasatobunkovou leukémiou.
litak has been examined in one main study involving 63 patients with hairy cell leukaemia.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Reference:
Warning: This alignment may be wrong.
Please delete it you feel so.
liek litak sa skúmal v jednej hlavnej štúdii, ktorá zahŕňala 63 dospelých pacientov s vlasatobunkovou leukémiou.
litak has been examined in one main study involving 63 adults with hairy cell leukaemia.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
toto mierne zvýšené riziko môže byť spôsobené vlasatobunkovou leukémiou alebo terapiou používanou na liečbu tohto ochorenia vrátane litaku.
this slightly increased risk can be due to hairy cell leukaemia or to therapies used to treat the disease including litak.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
u väčšiny pacientov s vlasatobunkovou leukémiou sa v priebehu jedného až dvoch mesiacov liečby introna dostaví normalizácia jedného alebo viacerých hematologických parametrov.
for most patients with hairy cell leukaemia, normalisation of one or more haematological variables occurs within one to two months of introna treatment.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
frekvencia ďalších malígnych afekcií po liečbe litakom dosiahla u všetkých 232 pacientov s vlasatobunkovou leukémiou 3, 4% za obdobie 10 rokov.
the frequency of second malignancy following treatment with litak was 3.4% in all 232 hairy cell leukaemia patients treated during a 10-year period.
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
Reference:
keďže je počet pacientov s vlasatobunkovou leukémiou nízky, toto ochorenie sa považuje za zriedkavé a preto bol liek litak 18. septembra 2001 označený za liek na ojedinelé ochorenia.
because the number of patients with hairy cell leukaemia is low, the disease is considered ‘rare’, and litak was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 september 2001.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
kultivačne negatívna horúčka po liečbe kladribínom sa vyskytuje u 10 – 40% pacientov s vlasatobunkovou leukémiou a zriedkavo sa pozoruje u pacientov s inými neoplastickými poruchami.
culture-negative fever following treatment with cladribine occurs in 10-40% of patients with hairy cell leukaemia and is rarely observed in patients with other neoplastic disorders.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
počas klinického skúšania subkutánne podávaného litaku bolo liečených 63 pacientov s vlasatobunkovou leukémiou (33 novo diagnostikovaných pacientov a 30 pacientov s recidívou alebo progresiou choroby).
in the clinical trial using litak subcutaneously, 63 patients with hairy cell leukaemia (33 newly diagnosed patients and 30 patients with relapsed or progressive disease) were treated.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
keďže pacienti s aktívnou vlasatobunkovou leukémiou majú väčšinou zhoršený krvný obraz, najmä nízke počty neutrofilov, viac než 90 % prípadov má prechodnú silnú neutropéniu (< 1,0 x 109/l).
since patients with an active hairy cell leukaemia mostly present with low blood counts, especially low neutrophil counts, more than 90% of the cases have transient severe neutropenias (< 1.0 x 109/l).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
Warning: Contains invisible HTML formatting